Relay Therapeutics, Inc.
Moat Score — Relay Therapeutics, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Relay's Dynamo computational/biophysical drug discovery platform and related patent filings represent real proprietary technology, though it has not yet produced an approved, revenue-generating product. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage company with no commercial products, Relay has no cost advantage; it is purely an R&D-stage cost center funded by capital markets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Relay has no approved products and therefore no current pricing power; any future pricing power is entirely speculative and contingent on trial success and approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in drug discovery or clinical-stage biopharmaceutical development. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product, there are no customers or prescribers to create switching costs at this stage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Precision oncology drug discovery requires substantial R&D investment and specialized computational expertise, a moderate barrier to entry, though many well-funded competitors pursue similar targets. |